| 摘要: |
| ［摘要］ 激素受体（HR）阳性/人表皮生长因子受体2（HER2）阳性乳腺癌在分子功能、生物过程、信号通路、临床行为、治疗敏感性和内在生物学方面与其他分子亚型乳腺癌存在差异，因此被认为是乳腺癌分子分型中较为特殊的一类。目前，HR阳性/HER2阳性乳腺癌在治疗策略的选择上存在较多的争议和不确定性。如何选择疗效更好、安全性更高、可及性更强的治疗策略，是目前及将来较长一段时间内需要探索的问题。该文将通过新辅助和辅助治疗阶段多个临床研究中HR阳性/HER2阳性乳腺癌患者的相关数据进行分析，从数据中找寻HR阳性/HER2阳性乳腺癌患者的特殊性，为制定更适合的个体化治疗策略提供依据。 |
| 关键词: 乳腺癌 人表皮生长因子受体2阳性 激素受体阳性 治疗策略 |
| DOI：10.3969/j.issn.1674-3806.2022.06.03 |
| 分类号:R 737.9 |
| 基金项目:中国抗癌协会HER2靶点中国科研基金项目（编号：CORP-239-S5）；长沙市科技计划项目（编号：kq2004137） |
|
| Treatment options and considerations of HR-positive/HER2-positive early breast cancer |
|
LIU Bin-liang, XIE Ning, OUYANG Qu-chang
|
|
Department of Breast Cancer Medical Oncology, Hunan Cancer Hospital, the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China
|
| Abstract: |
| ［Abstract］ Human epidermal growth factor receptor 2(HER2)-positive with hormone receptor(HR)-positivebreast cancer is considered as a relatively special type of breast cancer due to its differences in molecular function, biological process, signaling pathway, clinical behavior, treatment sensitivity and intrinsic biology from other molecular subtypes of breast cancer. At present, there are many controversies and uncertainties in the selection of treatment strategies for HR-positive/HER2-positive breast cancer. How to choose a treatment strategy with better efficacy, higher safety and better accessibility is an issue that needs to be explored at present and in the future for a long time. In this paper, the relevant data of patients with HR-positive/HER2-positive breast cancer in multiple clinical studies in neoadjuvant and adjuvant therapy settings will be analyzed to find out the particularity of HR-positive/HER2-positive breast cancers, so as to provide a basis for the development of more suitable individualized treatment strategies. |
| Key words: Breast cancer Human epidermal growth factor receptor 2 positive Hormone receptor positive Treatment strategy |
